Study to Evaluate the Efficacy and Safety of SHR6390 Combined With Pyrotinib in HER2+ Advanced Breast Cancer

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
The main purpose of this study was to observe the efficacy and safety of treatment with pyrotinib and CDK4/6 inhibitor SHR6390 for HER2-positive metastatic breast cancer.
Epistemonikos ID: 2a5c9952c79b2a72c3c160a9597ab1c57c698fdc
First added on: May 07, 2024